Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Swedish Orphan Biovit Ord (BIOVF)

Swedish Orphan Biovit Ord (BIOVF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Has Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?

Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

BIOVF : 21.2000 (-1.03%)
EDAP : 7.49 (-1.71%)
Swedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?

Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

BIOVF : 21.2000 (-1.03%)
CHRS : 11.41 (-3.55%)
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Lags Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -16.09% and 27.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

SPRO : 0.8207 (+2.59%)
BIOVF : 21.2000 (-1.03%)
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 1.9900 (+5.29%)
BIOVF : 21.2000 (-1.03%)
Rapt Therapeutics (RAPT) Reports Q1 Loss, Tops Revenue Estimates

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of -4.55% and 60.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RAPT : 21.68 (+1.26%)
BIOVF : 21.2000 (-1.03%)
Earnings Preview: Swedish Orphan Biovitrum (BIOVF) Q3 Earnings Expected to Decline

Swedish Orphan Biovitrum (BIOVF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BIOVF : 21.2000 (-1.03%)

Barchart Exclusives

Marathon Oil Massive Buybacks Facilitate Covered Call Plays
Marathon Oil and Gas reported a record adjusted free cash flow for Q2 on Aug. 4. The company is using most of this cash flow to buy back large amounts of its stock, benefiting investors selling covered calls. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar